Eastern Michigan University

DigitalCommons@EMU
Master's Theses and Doctoral Dissertations

Master's Theses, and Doctoral Dissertations, and
Graduate Capstone Projects

2012

Experimental simulation of human islet amyloid
polypeptide (hIAPP)-pancreatic beta cell
membrane interactions: Inferences and
implications in the etiopathogenesis of diabetes
mellitus type II
Sarika Pamarthy

Follow this and additional works at: http://commons.emich.edu/theses
Part of the Physical Sciences and Mathematics Commons
Recommended Citation
Pamarthy, Sarika, "Experimental simulation of human islet amyloid polypeptide (hIAPP)-pancreatic beta cell membrane interactions:
Inferences and implications in the etiopathogenesis of diabetes mellitus type II" (2012). Master's Theses and Doctoral Dissertations. 854.
http://commons.emich.edu/theses/854

This Open Access Thesis is brought to you for free and open access by the Master's Theses, and Doctoral Dissertations, and Graduate Capstone Projects
at DigitalCommons@EMU. It has been accepted for inclusion in Master's Theses and Doctoral Dissertations by an authorized administrator of
DigitalCommons@EMU. For more information, please contact lib-ir@emich.edu.

Theses and Dissertations

Masters Thesis and Doctoral Dissertations
Eastern Michigan University

Year 2012

Experimental Simulation of Human Islet Amyloid polypeptide
(hIAPP)-Pancreatic Beta Cell Membrane Interactions:Inferences and
Implications in the Etiopathogenesis of Diabetes mellitus Type II

Sarika Pamarthy

Experimental Simulation of Human Islet Amyloid polypeptide (hIAPP)-Pancreatic Beta Cell
Membrane Interactions:Inferences and Implications in the Etiopathogenesis of Diabetes
mellitus Type II

by
Sarika Pamarthy

Thesis

Submitted to the Department of Chemistry
Eastern Michigan University
In partial fulfillment of the requirements
For the degree of
MASTER OF SCIENCE
in Chemistry

Deborah Heyl-Clegg, PhD, Chair
April 17, 2012
Ypsilanti, Michigan

This thesis work is dedicated to
Sai Baba, the wirepuller and caretaker of all living creatures.

i

THESIS APPROVAL FORM
Experimental Simulation of Human Islet Amyloid polypeptide (hIAPP)-Pancreatic Beta Cell
Membrane Interactions:Inferences and Implications in the Etiopathogenesis of Diabetes
mellitus Type II
by
Sarika Pamarthy

APPROVED:

________________________________
Director: Dr. Deborah Heyl-Clegg, PhD

___________________
Date

Thesis Chair

_________________________________
Dr. Maria Milletti, PhD

__________________
Date

Committee Member

_________________________________
Dr. Timothy Brewer, PhD

_________________
Date

Committee Member

_________________________________
Dr. Ross Nord, PhD

__________________
Date

Department Head

_________________________________
Deborah de Laski-Smith, PhD

__________________
Date

Dean of the Graduate School

ii

ACKNOWLEDGEMENT
Writing my thesis, the journey: The timing of my research completion perfectly coincided
with our scientific publication, providing a strong impetus with which I could lay down the
initial framework of my thesis. I must admit the journey has been arduous, fraught with
several dilemmas and painful moments. Time management during multitasking, critical
analysis of our own work in the light of available literature, bridging theory and application,
dealing with people both inside and outside our department, learning new research
techniques, operating independently and as part of a team and most importantly writing,
communication and presentation skills were several components that made this process
extremely challenging but well worth the effort. In retrospect, I am thankful for the
invaluable lessons and practical experience that I believe will propel me forward in the
scientific arena.

---------------------------------------------------------------------------------------------------------------First and foremost, I would like to thank Sai Baba, my spiritual master, for directing the
course of my life as the great wirepuller. I feel very privileged to study a microcosm of HIS
creation, the universal laboratory, through protein chemistry. I am thankful for Baba’s grace,
which saw me through the completion of this project in HIS perfect time.

I would like to thank Dr. Deborah Heyl-Clegg from the bottom of my heart for her
unwavering support as a mentor, both within and outside the lab. Right from the early days of
my association with Dr. Heyl-Clegg, I never failed to receive undivided attention and
guidance despite her busy schedules and innumerable students seeking her time.

iii

She has always been extremely approachable, and her ever-pleasant disposition makes her an
ideal role model worth emulating. I feel very fortunate to have been associated with her and
wish well for her and her family.

I would like to gratefully acknowledge Dr. Timothy Brewer for being a wonderful graduate
coordinator. After several semesters of interaction with Dr. Brewer, I feel extremely fortunate
to have experienced his simplicity, fairness, and accommodating nature. I would also like to
thank Dr. Brewer for accepting responsibility as one of my thesis committee members and for
his critical review of my thesis work. I could not have asked for a better guide as an
international student with little knowledge of graduate school dynamics in the U.S.

I would like to acknowledge the guidance and support extended by Dr. Maria Milletti, who is
also one of my thesis committee members. Dr. Milletti has been instrumental in providing
extremely detailed molecular modeling results, which was of great help in our analysis. Dr.
Milletti’s attention to detail and great work ethic has also been very inspiring. I would like to
thank Dr. Milletti for taking the time to review my thesis and offer valuable suggestions in a
short time frame.

I would like to applaud Dr. Ross Nord, head of the department, for his leadership skills and
effective management of the department. I particularly appreciate Dr. Nord for
accommodating my thesis review in his busy schedule and providing a positive critique that
has allowed me to refine my work.

iv

I would like to thank Dr. Jefferey R. Brender and Andrew Thiggs at the Departments of
Chemistry and Biophysics at the University of Michigan for their time, technical guidance,
training, and collaboration during the final stages of our project. I would also like to
acknowledge the help extended by Carol and Brian while managing requirements at the
departmental seminars and meetings, thank you very much.

I would like to thank Dr. Lorraine Fig, University of Michigan, for her affection, support, and
great faith in my capabilities.

I would also like to thank my family, my parents, Raja Ram Mohan Roy and Sharada, my
brother and sister, Sharath Chandra and Deepika, and Softy for all the love, blessings, and
goodness in life.

The time I have spent at Eastern is memorable, and I owe a lot to the friends that I have found
here. The love and support from innumerable friends at Eastern (notably Srinivas Patnaik
Satumahanthi, Monis Hussain Syed, Soujanya Tetali, Ranadheer Pesaru, and many others
whom I do not mention for lack of space) saw me through thick and thin; without all of you I
would not have made it. I would like to make a special mention of Vasumathi and Shyam
Prasad Samisetti who were instrumental in introducing me to the Chemistry department,
thank you very much.

I would like to highly commend the Halle Library resources and excellent staff who are ready
to help often at odd hours of the day and night (!). The times spent at the library will not be
forgotten.
v

This work was supported by an award of Research Corporation (DLH). MCM is grateful to
the National Center for Supercomputing Applications (NCSA) for access to their computing
resources (grant TG-CHE070010N).

vi

Abstract
Pancreatic beta cells secrete insulin, an endocrine hormone that regulates blood glucose
levels and maintains normal physiological activity in humans and animals. Diabetes mellitus
type II is a consequence of the gradual destruction of these important cells, likely by human
islet amyloid polypeptide (hIAPP) that is co-secreted with insulin. Increasing health care
costs, coupled with the World Health Organization’s prediction of a worldwide diabetic
epidemic by year 2030, make experimental diabetes research a crucial prologue to future
clinical trials in prevention, diagnosis, and treatment of Diabetes mellitus type II.
Our experimental set-up simulates hIAPP peptide fragment and pancreatic beta cell
membrane interactions, and it uses density functional methods and circular dichroism
spectroscopic analysis of the hIAPP molecule to uncover factors that initiate and promote
progression of beta cell death. Results from our study establish the potential role of hIAPP
and a two-step molecular mechanism of pancreatic beta cell damage in diabetes mellitus type
II.
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1. Introduction

Diabetes mellitus: an overview and current statistics

1.1 Normal anatomy and physiology of the pancreas

The pancreas (Figure 1) is an important abdominal organ located in close relationship
to the duodenum and small intestine in most animals, with exocrine and endocrine functions.
The exocrine part of the pancreas produces enzymes, most importantly trypsin, amylase, and
lipase, that aid digestion of proteins, carbohydrates, and fat in food within the gastrointestinal
tract. The endocrine portion secretes multiple hormones directly into the blood stream, most
importantly, insulin and glucagon to modulate blood glucose levels and maintain normal
physiological activity in humans and animals (1).

Figure 1. Gross anatomy of the pancreas.
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1.2 Cytoarchitecture of the pancreas
The “islets of Langerhans” are small clusters of cells that constitute the functional
units of the endocrine pancreas. While a German pathological anatomist Paul Langerhans
discovered these islets during his doctoral studies at the Berlin Pathological Institute in the
year 1869, a French pathologist and histologist, Edouard Laguesse of Lille, named them the
“islets of Langerhans” much later in 1893. Laguesse also postulated that these cells produced
an internal secretion, which was named “isletin” after the islets of Langerhans and later
changed to insulin in about 1923. Laguesse’s findings were considered to be a major step in
the discovery of hormones in the early days of endocrinology (2,3).

A healthy adult human pancreas contains about one million islets of Langerhans,
found in higher concentrations within the pancreatic tail region. The mass of the islets is
approximately 1-1.5 grams, making up 1-2 % of the weight of the pancreas, which is roughly
about 100 gm in a person weighing about 70 kg (4,5).
The “islets of Langerhans” contain multiple cell types including alpha, beta, delta,
epsilon, and F cells, responsible for production of several peptide hormones: glucagon,
insulin and amylin, somatostatin, pancreatic polypeptide, and ghrelin, respectively. These
peptide molecules, most importantly insulin and glucagon, play a vital role in the tight
regulation of blood glucose metabolism required for normal homeostasis. The histology of
the normal pancreas can be seen in Figure 2.
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Figure 2. Histology of the normal pancreas.

1.3 Insulin and Amylin

Small quantities of Amylin or human Islet Amyloid Polypeptide (hIAPP) are cosecreted by the pancreatic beta cells with insulin, in an approximate ratio of 1:100. The
presence of excess amounts of hIAPP, a 37 amino acid peptide, is implicated as an important
etiological factor in pancreatic beta cell destruction.
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The clinical disease Diabetes mellitus type II occurs as a terminal consequence of the
gradual and irreversible destruction of these cells. This is a progressive disease associated
with insufficient insulin production and insulin resistance. In the first phase of the disease, the
body becomes insensitive to insulin, which may be partly compensated for by increased
insulin secretion from pancreatic beta cells. In the second phase, the production of insulin
declines as these insulin producing beta cells begin to die. Amyloid deposits in pancreatic
islets have been commonly found in Diabetes mellitus type II patients.

1.4 History of Amyloid discovery and association with Diabetes mellitus.
Rudolph Virchow, a German physician scientist, introduced the term “amyloid” in
1854. Based on the pale blue staining of cerebral corpora amylacea on treatment with iodine,
he concluded that the given substance was likely starch or cellulose (carbohydrate). He
named it “amyloid”, derived from the Latin amylum and the Greek amylon. A few years later
in 1859, after several chemical investigations, Carl Friedreich and August Kekule
demonstrated two important things: the presence of protein in a “mass” of amyloid and the
apparent absence of carbohydrate based on the high nitrogen content. Amyloid was then
considered a protein and subsequently a class of proteins, with a propensity to undergo
conformational changes resulting in fibril formation.
It was not until the year 1901 that Eugene L. Opie, a medical student, first discovered
the association between hyaline material deposited in the pancreatic islets and diabetes. The
histopathology of this hyaline material was ascertained as amyloid in 1943 and later
confirmed by alkaline Congo red staining and electron microscopy identification of fibrillar
structure (6,7,8).
4

1.5 hIAPP gene structure

The total size of the gene for hIAPP is 6599 base pairs (Entrez gene id: 3375). The
precursor protein, “preprohIAPP,” contains 89 amino acids confirming its cellular
secretion/origin (Refseq: NP_000406). Its mRNA is 1462 base pairs long and contain 3
exons (NM_000415). It is located on chromosome 12 (NC_000012.10) of the human
genome, gene locus is 12p12.3-p12.1. The peptide is unique but shares common amino acids
with calcitonin (9).

1.6 Diabetes mellitus: basic concepts

The lack of normal concentration of insulin in the bloodstream of a human or animal
leads to a disease condition known as Diabetes mellitus. It is one of the most common
chronic human metabolic diseases and is of two major types.

Diabetes mellitus type I: commonly referred to as insulin-dependent or childhood-onset
diabetes. This subset has a younger age of onset and results from insufficient production of
insulin (quantitative defect) and accounts for 5-10% of the cases. There is gradual
destruction and decrease in number of pancreatic beta cells either directly by viral infections
(EMC virus, Mengo virus 2T, Coxsackie B4 viruses) or autoimmune mechanisms.

Diabetes mellitus type II: commonly referred to as non-insulin-dependent or adult-onset
diabetes. This subset has an older age of onset, is associated with genetic factors, obesity, and
physical inactivity, and usually makes up 90-95% of the cases. These diabetogenic factors
lead to increasingly worsening pancreatic beta cell defects and insulin resistance.

5

The initial decreased tissue responsiveness or resistance to normal amounts of
secreted insulin paralleled by gradual destruction of pancreatic beta cells leads to an
irreversible phase of insulin deficit (initial qualitative defect followed eventually by a
quantitative deficit).

Figure 3. Brief mechanism of beta cell damage by hIAPP.

These two processes occur simultaneously, leading to ultimate beta cell failure,
explained graphically in Figure 3. Pancreatic beta cell defects cause decreased insulin release,
leading to gradual increase of blood glucose concentration (hyperglycemia) above normal
physiologic levels. This hyperglycemia imposes an increased insulin demand on the
pancreatic beta cells with coincidental increased release of amylin (hIAPP), normally
cosecreted with insulin. As both these processes occur simultaneously, it leads to a gradual
spiralling of the disease process, resulting in the clinical symptoms and physical
manifestations of Diabetes mellitus.
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The hIAPP polypeptide is postulated to be the causative factor in pancreatic beta cell
damage and is associated with lowered insulin secretion in Diabetes mellitus type II. hIAPP
has been identified in postmortem pancreatic islet specimens of Diabetes mellitus type II. In
humans, amyloid is found more frequently in older diabetic patients, especially in severe
diabetes requiring insulin therapy (10). hIAPP forms plaques via sequential fibril formation
and aggregation, processes that are intimately linked to and hypothesized to cause
simultaneous disruption of beta cell membranes leading to eventual cell death. The terminal
consequence of this process is gradual beta cell destruction and decreasing pancreatic beta
cell mass with subsequent total failure of insulin secretion due to irreversible pancreatic beta
cell destruction. Interestingly, an insulin binding area has been identified on the hIAPP
molecule, and it has been observed that normal levels of secreted insulin actually limit the
beta cell damage caused by this peptide (11). In summary, gradual hIAPP deposition leading
to islet amyloidosis can be considered both a cause and an effect of the disease process.

1.7 Amyloidosis and Amyloid associated diseases
In Diabetes mellitus type II and multiple other diseases, inflammatory responses
responsible for the disease are postulated to occur either due to amyloid formation or
misfolding of normal protein molecules (12,13). Table 1 below lists the disease and the
respective protein implicated in each disease process. About 23 different subtypes of amyloid
associated proteins have been described with symbols, A standing for amyloid and the
following letter for the precursor protein, e.g. A protein in Alzheimer’s disease is Amyloid
beta protein.
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Table 1. Amyloid associated diseases and the implicated proteins.
Disease

Protein

Diabetes mellitus type II

Amylin or hIAPP

Alzheimer’s disease

A protein

Parkinson’s disease

 Synuclein

Huntington’s disease

Huntingtin

Secondary systemic amyloidosis

Amyloid A

Senile systemic amyloidosis

Transthyretin

Creutzfeldt Jacob/ “Mad cow” disease

Prion protein

Multiple myeloma

Immunoglobulin heavy chain

Hemodialysis related amyloidosis

A2 Microglobulin

An underlying common mechanism of amyloid- and other protein-induced cell death
in various organ systems of the body has been proposed and investigated by researchers. This
would help identify a common etiological basis and unifying mechanism that would
indirectly lead to the formulation of a common solution to multiple diseases.

In our study, exploration of the structural characteristics and activity of various hIAPP
fragments would establish the potential role of the suspected disease causing regions within
the molecule. Based on this information, crucial applications in prevention and treatment of
this irreversible disease process can be formulated.
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1.8 Diabetes mellitus: worldwide distribution and health care costs.

World Statistics on Diabetes mellitus:

Once thought of as a disease of affluent countries, the WHO and International
Diabetes Federation now predict a “Diabetic epidemic” with globalization of the disease by
the year 2030. The global and regional distribution of Diabetes is shown in Tables 2 and 3,
respectively.
Table 2. Global burden: Prevalence and Projections, 2010 and 2030: This information
was obtained from the Diabetes Atlas maintained by the International Diabetes Federation
(IDF) (14).
2010

2030

Total world population (billions)

7.0

8.4

Adult population (20-79 years,

4.3

5.6

6.6

7.8

Comparative prevalence (%)

6.4

7.7

Number of people with diabetes

285

438

billions)
Diabetes and Impaired glucose
tolerance (IGT) (20-79 years)
Global prevalence (%)

(millions)
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Table 3. Regional distribution of Diabetes, comparing numbers in 2010 and 2030.

(Legend: AFR-Africa, EUR-Europe, MENA-Middle East and North Africa, NAC-North
America and Caribbean, SACA-South and Central America, SEA-South east Asia, WPWestern Pacific.)

A 2008 report by the World Health Organization (WHO) estimates about 2% of all
non-communicable disease (NCD) deaths worldwide to Diabetes (Figure 4), with
cardiovascular diseases responsible for the largest proportion of NCD deaths under the age of
70 (39%), followed by cancers (27%), chronic respiratory diseases, digestive diseases, and
other NCDs together responsible for approximately 30% of deaths (15).
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Diabetes
Cardiovascular diseases
Cancers
Other non-communicable
diseases

Figure 4. Worldwide distribution of non-communicable disease according to a 2008 W.H.O.
report.
In Diabetes mellitus, excess glucose in the bloodstream is gradually deposited and
transformed to fatty plaques leading to progressive damage of vital organs like the kidney,
heart, brain, and eyes. This multisytem damage mainly occurs via involvement of the blood
vessels supplying these organs (16).

National Statistics in the USA: A short summary of the compilation of disease incidence
and prevalence by the Center for Disease Control (CDC), Atlanta, using multiple data
systems, is shown below.
1) Among U.S. residents aged 65 years and older, 10.9 million, or 26.9%, had diabetes in
2010.
2) About 215,000 people younger than 20 years had diabetes (type 1 or type 2) in the United
States in 2010.
3) About 1.9 million people aged 20 years or older were newly diagnosed with diabetes in
2010 in the United States (16).
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Diabetes is the leading cause of kidney failure, nontraumatic lower-limb amputations,
and new cases of blindness among adults in the United States. Diabetes is also a major cause
of heart disease and stroke and is the seventh leading cause of death in the United States.
Lack of awareness of the disease process is partly due to the chronic and often gradual
destruction of beta cells, causing it to go unnoticed. There is little that can be done to reverse
full-blown disease. Hence, there is a great need for research in this area due to the
aforementioned reasons.

Total costs, including direct medical costs and indirect costs due to disability, work
loss, and premature mortality, are approximately $174 billion per year in the United States
(2007). As the population gets older, the impact of these diseases is expected to grow
dramatically.

1.9 Brief introduction of our laboratory research

The causative role of various regions of the 37 amino acid hIAPP molecule in
pancreatic beta cell membrane disruption has yet to be fully elucidated to understand the
pathogenesis of Diabetes mellitus. Our experimental set-up simulates interactions between
individually synthesized, overlapping hIAPP fragments (1-19, 10-29, 10-19, 20-29) and
liposomes (analogous to artificial pancreatic beta cell membranes) in two types of
fluorescence-based assays that examine and uncover possible factors that initiate pancreatic
cell membrane damage.
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Cross comparison of individual fragment behaviour to the activity of the full-length
hIAPP molecule, with positive controls (100% destruction of lipid vesicles exposed to known
strong detergent agents) and negative controls (lipid vesicles that were neither exposed to
detergent, hIAPP nor hIAPP fragments), helped to establish the validity of our experimental
method.
Liposome disruption equivalent to pancreatic beta cell membrane damage,
predominantly caused by particular fragments of the hIAPP molecule, was identified by the
carboxyfluorescein dye leakage assay. Amyloid fibril forming capability, an indirect measure
of the individual fragments’ tendency to build upon initial membrane damage and eventually
cause progressive beta cell death, was analyzed via fragment activity in a Thioflavin based
assay.
Additionally, computational work using density functional methods was used to
construct individual hIAPP fragment conformations and study the electron/charge
distribution along these fragment models to predict relative activity of fragments. This
theoretical explanation of fragment activity performed by another independent research team,
blinded to our wet lab work, strongly validated our experimental data and results.
Last, a fourth independent method, circular dichroism (CD) spectroscopy, was used to
conclude our investigation of the hIAPP molecule. CD spectroscopic analysis of structural
conformation of individual fragments was used to correlate structure-activity relationships
over fixed time periods consistent with the time scale used for the previous assays and also
with the theoretical data from the computational study.
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These results were used to establish, with a very high degree of certainty, the sinister
areas or culprit fragments of hIAPP involved in initiation and acceleration of the pancreatic
beta cell membrane destruction that culminates in the pathologic state of Diabetes mellitus
type II.
The results from all the four independent and established scientific methods are used
to compare and contrast between activity levels and to clearly delineate the potential role of
various fragments of hIAPP in the disease process. Finally, a coherent sequence of possible
molecular mechanisms causing pancreatic damage can be formulated, reiterating
contemporary work by other research groups in the synthetic peptide chemistry field.
Comparison with other large studies has also been made to standardize our analysis.
In light of the World Health Organization’s prediction of a worldwide diabetic
epidemic by year 2030, coupled with an ever-increasing global need for cost-effective health
care, experimental diabetes research is a crucial prologue to future clinical trials in
prevention, diagnosis, and treatment of Diabetes mellitus type II. The extremely small mass
of the pancreatic beta cells relative to the body weight, their critical responsibility in glucose
metabolism during the entire lifetime of an organism, and the clinical, financial consequences
of Diabetes mellitus type II on society necessitates extensive research in this area.
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2. Research Goals

The working hypothesis of our research is that the presence of plaques and deposits of
hIAPP within the pancreas of patients with Diabetes mellitus type II suggests its likely role in
the etiology and pathogenesis of this disease process. Interestingly, amyloid has also been
implicated in Parkinsonism, Alzheimer’s disease, multiple myeloma, rheumatoid arthritis and
Huntington’s disease. An underlying common mechanism of amyloid-induced cell death in
various organ systems of the body has led to a new disease entity, “Amyloid associated
disease,” which seeks to bring together a common etiological basis that would indirectly lead
to the formulation of a common solution for all these disease processes.
We had two main goals for our project. Our experimental set-up simulates hIAPP and
pancreatic beta cell membrane interactions to uncover factors that initiate and promote
progression of beta cell death.
We also explored two important mechanisms of pancreatic cell death: cell destruction
via membrane pore formation by various hIAPP fragments and amyloidogenic fibril
formation by fragments of hIAPP leading to fibril-dependent cell membrane destruction. The
observations and results of our study establish the precise portions of hIAPP that can cause
pancreatic damage and help elucidate the molecular mechanisms of activity by the implicated
toxic species. It also provides an opportunity to explore the cellular environment affecting the
formation of hIAPP aggregates and devise methods to intervene and prevent hIAPP
aggregation and subsequent pancreatic cell death that leads to Diabetes mellitus type II.
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3. Materials and Methods
3.1 Peptide synthesis

3.1.1 Discovery of the amide or peptide bond.
The peptide bond is integral to the biochemistry of all living organisms as it forms a
link between two amino acids, the building blocks of proteins. In 1902, Emil Fischer, a
German chemist, became a Nobel laureate for his work in the field of carbohydrate
chemistry; at this time he also made great contributions to the knowledge of proteins and
amino acids. He studied the synthesis of proteins by obtaining the various amino acids in an
optically active form. His initial synthesis of glycyl-glycine in 1901 represents the first
synthesis of a free peptide. Fischer later reported the synthesis of an octadecapeptide (LeuGly3-Leu-Gly3-Leu-Gly9) in 1907. Additionally, Fischer also initiated peptide nomenclature
by naming his first byproduct a “dipeptide,” thereby defining the terminology of peptide
chemistry that is used to date (17). Fischer’s discovery was futuristic and laid the cornerstone
for peptide research and peptide therapeutics leading to development of innumerable drugs
and diagnostic methods.

3.1.2 History of solid phase peptide synthesis techniques: R.B. Merrifield and his
contributions.
Dr. Robert Bruce Merrifield, an American biochemist, is the pioneer of solid phase
peptide synthesis and received the Nobel Prize for this invention in 1984. His initial
discovery of a dinucleotide peptide growth factor during his graduate studies later led to the
development of the solid peptide synthesis technique in 1959.
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The methods available until then were fraught with technical difficulties related to
solubility and purification and were not ideally suited for long chain polypeptide synthesis.
Dr. Merrifield investigated a new approach to peptide synthesis in an effort to overcome
some of these difficulties. He was the sole author of a paper describing this technique to
synthesize a model tetrapeptide, L-leucyl-L-alanylglycyl-L-valine, in the Journal of the
American Chemical Society, the fifth most cited paper in the journal's history (18).

Subsequently, Dr. Merrifield's laboratory first synthesized bradykinin, angiotensin,
desamino-oxytocin, and insulin. In 1969, Dr. Merrifield and Bernd Gutte first synthesized the
enzyme ribonuclease A, proving the chemical nature of enzymes. This was a significant step
that demonstrated the functional influence of the three-dimensional, tertiary structure of a
peptide or protein containing a linear sequence of amino acids joined by peptide bonds.

Dr. Merrifield's method allowed systematic exploration of the structural basis of
peptide chemistry. The study of enzymes, hormones, and antibodies greatly stimulated
progress in biochemistry, pharmacology, and medicine. The development and applications of
the technique have been expanded to include solid phase synthesis of nucleotides and
saccharides. In 1993, he published his autobiography, Life During a Golden Age of Peptide
Chemistry. He also received the Association of Biomolecular Resource Facilities (ABRF)
Award for outstanding contributions to Biomolecular Technologies in 1998. ABRF members
represent 41 different countries across the world.
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The abstract of Dr.Merrifield’s paper reads, A new approach to the chemical
synthesis of polypeptides was investigated. It involved the stepwise addition of
protected amino acids to a growing peptide chain, which was bound by a covalent
bond to a solid resin particle. This provided a procedure whereby reagents and byproducts were removed by filtration, and the recrystallization of intermediates was
eliminated. The advantages of the new method were speed and simplicity of
operation. The feasibility of the idea was demonstrated by the synthesis of the model
tetrapeptide L-leucyl-L-alanylglycyl-L-valine. The peptide was identical with a
sample prepared by the standard p-nitro-phenyl ester procedure.

To explain further, Dr. Merrifield proposed the use of a solid phase, an insoluble
polymer with stable physical form and a functional group, for temporary covalent bond
formation with the first amino acid in the peptide chain to be synthesized. This polymer
surface and/or the first covalently bound amino acid provide a starting point for peptide
synthesis and allow addition of a desired sequence of amino acids to the free end of the first
amino acid. Finally, the peptide is separated from the solid polymer supporting it, and pure
peptide is harvested and analyzed via chromatography. (Figure 5 shows the stepwise
flowchart of peptide chemical synthesis, and Figure 6 shows a ball and stick model of
synthesized peptide.)

The polymers available at that time were cellulose, polyvinyl alcohol,
polymethacrylate, and sulfonated polystyrene. The one that worked best was a
chloromethylated copolymer of styrene and divinylbenzene. The solid phase or resin, in the
form of 200-400 mesh beads, possessed a porous gel structure, allowing ready penetration of
reagents during chemical reaction.
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In addition, it also allowed purification of intermediate peptides by washing and
dissolving away the impurities instead of the usual lengthy recrystallization procedures. This
greatly improved productivity and working time by simplifying multiple intermediate
chemical manipulations related to the peptide synthesis flowchart. Dr. Merrifield’s
methodology, which has now lent itself to automation, also provides a tireless route to the
synthesis of higher molecular weight polypeptides, inaccessible by conventional procedures.

The important limiting factors of this method, diffusion and steric hindrance, were not
serious enough to prevent completion of the required chemical reactions. Though individual
peptide bond reaction rates were slower than corresponding ones in solution, the conditions in
this method permitted all of the reactions to occur at useful rates. Since the growing peptide
chain was in the completely insoluble solid phase at all times, the term solid phase peptide
synthesis was coined to describe this method. The success of these initial experiments
ultimately demonstrated the feasibility of solid phase peptide synthesis. The real value of this
method lies in its later application to production of much longer peptide sequences, especially
those with biological activity.
3.1.3 Experimental hIAPP-pancreatic beta cell membrane interactions.
Dye leakage assays: Synthesis of hIAPP fragments and dye containing liposomes.
Several standard and proven methods used within our experimental set-up allowed us
to achieve our project goals. While earlier studies suggested that the 20-29 residues of the 37
amino acid long hIAPP mainly influence its aggregation during amyloidogenesis, the novel
part of our study included synthesis and testing activity of multiple shorter fragments of the
hIAPP molecule with varying peptide lengths (1-19, 10-19, 20-29, and 10-29 fragments).
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These fragments allowed us to examine the experimental behavior of various portions
of the hIAPP molecule during their interactions with the dye containing lipid vesicles or
liposomes that are analogous to pancreatic beta cell membranes in our study.

There were two types of dye assays used in our study: the carboxyfluorescein and
Thioflavin T assays, each with a different purpose. In the carboxyfluorescein dye assay, the
goal of the assay was to quantify the extent of liposome damage by individual hIAPP
fragments based on the percentage of carboxyfluorescein dye leakage. A spectrofluorometer,
a fluorescence sensor instrument, measured the amount of dye leakage. The Thioflavin T
assay was used to specifically identify amyloidogenic potential of each fragment after
liposome disruption. Thioflavin is a chemical dye that is widely used to visualize and
quantify the presence of misfolded protein aggregates such as amyloid. The chemical
Thioflavin, upon binding with or having specific chemical interaction with beta sheet rich
structures like those in amyloid aggregates, shows enhanced fluorescence and a characteristic
red shift of its emission spectrum identified on the spectrofluorometer.

Translation of research goals and the ideology behind our experimental set-up:
Our goal was to confirm previous reports (19, 20, 21) related to activity of various
regions within the hIAPP molecule. The N-terminus of the hIAPP peptide was implicated in
the initiation of vesicle damage by insertion into the lipid vesicles, to be identified by
liposome leakage of carboxyfluorescein or Thioflavin T dye in the two different assays.
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Accordingly, the full-length peptide and the 1-19 fragment must be able to cause
significant vesicle damage, while the 10-19 fragment (containing the insulin binding region)
and the 20-29 fragment (containing the amyloid-causing portion) should have lower levels of
liposome disruption. A second observation was the requirement of the amyloidogenic region
(20-29 fragment) in causing amyloidogenesis, which should be seen maximally with the fulllength amylin/hIAPP, followed by the 10-29 and 20-29 fragments. The 1-19 and 10-19
fragments, which lack this region, should intuitively show weaker amyloidogenesis.
The main focus of my research project revolved around the activity of the 20 amino
acid long 10-29 fragment that has overlapping activity with the three other fragments: 1-19,
10-19, and 20-29. This fragment showed overlapping behavior traits with other fragments due
to the partial presence of the N terminal amino acid residues and complete presence of the
insulin binding and amyloidogenic 20-29 regions. We were able to successfully study
individual interactions of the fragments with the liposomes during the experimental
simulation. We were also able to identify whether or not the overlapping portions of the
fragments had any significant influence on the degree of membrane disruption and the
potential for amyloidogenesis.
3.1.4 Brief summary of the experimental procedure
The experimental procedure began with customized peptide fragment synthesis from
individual amino acids utilizing the PS3 Solid Phase Peptide Synthesizer. Peptide cleavage
from the resin was followed by filtration and lyophilization (in simple terms, freeze drying
the solution to obtain the peptide in solid form). High levels of peptide purification were
achieved (>95%) using RP-HPLC (Reverse Phase-High Performance Liquid
Chromatography) techniques, and peptide identity was confirmed via Electrospray Mass
Spectrometric evaluation of molecular weights of the individual hIAPP peptide fragments.
21

The next step involved modeling cell membranes with uniformly sized unilamellar
lipid vesicles, with a similar composition as that of the pancreatic beta cell membrane, using
a 7:3 ratio of DOPC: DOPS (1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2dioleoyl-sn-glycero-3-(phospho-L-serine) (DOPS)). Carboxyfluorescein dye was
encapsulated within these overall negatively charged phospholipid vesicles.
Varying concentrations (0.5-50 M) of the synthesized hIAPP fragments were
exposed to fixed concentrations of the dye encapsulated lipid vesicles in an experimental
simulation of hIAPP-pancreatic beta cell membrane interactions that occur in vivo. Peptide
and vesicle ratios were within biological range, and controls were used for comparison.
The Spectrofluorometer quantified dye leakage from disrupted lipid vesicles, recorded
every minute over 4-6 hour intervals. The extent of fluorescence detected is suggestive of the
level of interaction between the fragments and the liposomes, with higher values suggesting
greater membrane destruction by specific fragments.
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Figure 5. Flowchart of solid phase peptide synthesis.

http://www.sigmaaldrich.com/life-science/custom-zoligos/custom-peptides/learningcenter/solid-phase-synthesis.html (Accessed October 2011-10-13)
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Figure 6. Ball and stick visualisation of solid phase peptide synthesis; peptide bonds linking
ball and stick forms of amino acids in various colors.
http://en.wikipedia.org/wiki/Peptide_synthesis
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3.1.5 Raw material required for solid phase peptide synthesis:

1) Amino acids: The initial part of our laboratory investigation was based upon interactions
between individually synthesized, overlapping hIAPP fragments (1-19, 10-29, 10-19, 20-29)
and dye containing lipid vesicles or liposomes (analogous to artificial pancreatic beta cell
membranes) in two types of fluorescence-based assays using carboxyfluorescein and
Thioflavin T. These assays were helpful in evaluation of varying levels of activity of the
different fragments of the hIAPP molecule in the initiation and progression of pancreatic cell
membrane damage in Diabetes mellitus type II.

Table 4. hIAPP full-length molecule and fragments overview: Amino acid sequence,
length and significance.

hIAPP
Fragment
1-19

Amino acid
length
19 amino acids

Amino acid sequence
KCNTATCATQRLANFLVHS

10-29

20 amino acids

QRLANFLVHSSNNFGAILSS

20-29

10 amino acids

SNNFGAILSS

10-19

10 amino acids

QRLANFLVHS

Full length
Amylin or
hIAPP

37 amino acids

KCNTATCATQRLANFLVHSSNNFGAILSSTNVGS
NTY
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Significance of
fragment
N-terminus and
insulin binding
region
Insulin binding and
fibril forming
amyloidogenic
region
Fibril forming
amyloidogenic
region
Insulin binding
region
1-37 amino acid
sequence from N to
C terminal

The smaller customized fragments of the hIAPP molecule were synthesized using
individual samples of the required regular N--fluorenylmethyloxycarbonyl (Fmoc)
protected amino acids, which were purchased from various chemical manufacturers
including Bachem Americas, Inc. (Torrance, CA), Anaspec (Freemont, CA), and
Synthetech, Inc. (Albany, OR). About fifteen of the twenty known amino acids were used
in chemosynthesis of the four hIAPP fragments (1-19, 10-29, 10-19, 20-29) with an
amidated C-terminus and an acetylated N-terminus, as described earlier.

Synthesis of the longer full-length human amylin (37 amino acids) requires a tightly
controlled environment and advanced instrumentation to ensure proper coupling and
purification of the long, aggregating sequence. Since this was not feasible in our
academic lab environment, a readymade commercially synthesized product was
purchased from SynBioSci (Livermore, CA). The hIAPP samples dissolved in
hexafluoroisopropanol (HFIP) were aliquoted, frozen, and lyophilized for use along with
the shorter fragments of hIAPP synthesized in our lab. Additionally, another mammalian
species, the rat IAPP, was studied and compared mainly with the hIAPP during molecular
modeling experiments in our project. The rats are supposed to be less prone to Diabetes
mellitus type II than humans mainly due to the differences in amino acid composition of
IAPP and secondary structure, which indirectly influence physiologic function.
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2) Resins and Coupling agents: These were purchased from Bachem Americas, Inc.,
and Midwest Biotech, Inc. (Fishers, IN). The role of the resin or solid phase material is
similar to a virtual platform where individual amino acids are lined up for peptide bond
formation. Additionally, during cleavage from the peptide, the resin also contributes the
carboxamide C terminus of a peptide fragment. The resin that was used is pmethylbenzhydrylamine (MBHA).

Coupling agents are chemicals that interact with functional groups on neighbouring
amino acids (amino, -NH2 and carboxylic acid, -COOH groups) to result in the formation of a
peptide bond. At the completion of peptide bond formation between all of the amino acids
arranged in a predetermined sequence, the resin and coupling agents need to be removed or
washed out.

In simple words, the creation of a peptide fragment with solid phase techniques can be
likened to threading beads on a string (Figure 7). The "beads" or individual amino acids, are
held together in a predetermined sequence by newly formed peptide bonds, which constitute
the invisible "string" in this analogy.

Figure 7. Sequence of the Human IAPP.
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3) Solvents and deprotecting agents were obtained from Fisher Scientific
(Pittsburgh, PA) and Sigma-Aldrich Chemical Co. (St. Louis, MO). Solvents are agents
that create a liquid environment for chemical interaction between the individual amino
acids while removing excess reagent surrounding the growing peptide in intermittent
wash cycles, while allowing the peptide itself to remain covalently attached to the
insoluble resin. Deprotecting agents used were helpful in uncovering a new N-terminal
amino group to which the next amino acid may be attached. Thus, repeated cycles of
amino acid coupling followed by solvent wash cycle, deprotection, and wash occur in
quick succession during the synthesis of a peptide chain in the solid phase peptide
synthesis technique.

3.1.6 Instrumentation and Procedural Detail of Solid Phase Peptide Synthesis:

Solid phase peptide synthesizer –chemosynthesis of hIAPP peptide fragments.

The peptides were chemically synthesized on a PS3 Automated Peptide Synthesizer
(Figures 8, 9, 10.) from Protein Technologies (Tucson, AZ) using standard solid phase
techniques (18) for N--fluorenylmethyloxycarbonyl (Fmoc) protected amino acids on
Rink amide p-methylbenzhydrylamine (MBHA) resin (0.64 mmole/g) on a 0.1 mmole
scale. A novel double couple protocol, set at a 0.4-mmol scale that requires four times the
usual amount of individual amino acids (raw material), was used for synthesis of the
longer fragments, 10-29 and 1-19. This method ensures more complete coupling than the
single couple method and improves the yield for longer sequences.
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Thus each amino acid was added in major excess (4x times), and pepide bond
formation between amino acids was highly optimized by a series of well-characterized
chemical agents. The purpose of utilizing large amounts of individual amino acids for
peptide fragment synthesis was to generate extremely high yield in each step. For
example, if each coupling step were to have 99% yield, a 26-amino acid peptide would be
synthesized in 77% final yield (assuming 100% yield in each deprotection); if each step
were 95%, it would be synthesized in 25% yield.
The MBHA resin contributes the amine part of the C-terminal carboxamide group of
the peptide fragment upon cleavage. The side chains of Ser and Thr were protected as the
t-butyl derivatives, Asn, Gln, His, and Cys as trityl, Lys as t-butyloxycarbonyl(Boc), and
Arg as the 2,2,5,7,8-pentamethylchroman-6-sulphonyl (Pmc) form. For the Ala-Thr
sequence in the hIAPP 1-19 analog, a pseudoproline/oxazolidine derivative [Fmoc-AlaThr (Me,Me pro)-OH] purchased from EMD Biosciences, Inc. (LaJolla, CA) was utilized
(22). The deprotection solution for the N-terminal amine was 20% piperidine in N,Ndimethylformamide (DMF). O-(Benzotriazol-1yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) was used as a coupling agent, activated by 0.4 M N,Ndiisopropylethylamine (DIEA) in DMF.
The N-terminal Fmoc group was removed, and simultaneous deprotection and
cleavage from the resin were accomplished by treatment with 11 ml 90% trifluoroacetic
acid (TFA)/10% scavenger cocktail (anisole, thioanisole, phenol, water). The reaction
was begun at 0C, allowed to warm to room temperature and stirred for 2 hours. The
uncharged resin was separated from the solution by filtration. The peptide was
precipitated with cold diethyl ether, filtered, redissolved in 30% acetonitrile/70% water
and lyophilized.
29

Figure 8. PS3 peptide synthesizer with components.

Figure 9. Reaction vessels with raw material.

Figure 10. Peptide filled vials arranged in required sequence.

Figures 12, 13. Lyophilization-freeze dried peptide.

Figure 11. Peptide-Resin cleavage.

Figure 14. Final peptide product.
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3.1.7 Instrumentation and Purification of crude peptides obtained from Solid Phase:

1) Preparative Reverse-Phase High Performance Liquid Chromatography (RP-HPLC):
The crude peptides were purified to homogeneity by preparative reversed-phase high
performance liquid chromatography (RP-HPLC) on a Waters (Milford, MA) instrument
with a Phenomenex (Torrance, CA) Jupiter C18 column (2.2 9 25.0 cm, 10 ml/minute). A
linear gradient of 10% acetonitrile (0.1% TFA)/water (0.1% TFA) to 50% acetonitrile
(0.1% TFA)/water (0.1% TFA) was employed, followed by lyophilization. The 1–19
fragment was oxidized in the presence of 20% dimethyl sulfoxide (DMSO) to form the
disulfide (23).

2) Analytical Reverse Phase – High Performance Liquid Chromatography (RP-HPLC) for
analysis of peptide purity:
The peptide purity was assessed by analytical RP-HPLC. Peaks were monitored at
214, 230, 254 and 280 nm. The peptides were 97% pure as analyzed by peak integration
(Figure 15 below). Electrospray mass spectrometry confirmed the appropriate molecular
weights (Figure 16 below).
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Figure 15.

Figure 16.

Figure 15. Reverse phase – High Performance Liquid Chromatography (RP-HPLC)- analysis
of peptide purity.
Figure 16. Electrospray mass spectrometry confirmation of the purity of the 10-29 peptide
fragment, peak readings of molecular weight of peptide tested measured 1087.7 (1087.7x 2 =
2174.4) corresponding to the weight of the 10-29 fragment.
3.1.8 Preparation of Large Unilamellar Vesicles (LUVs) and Dye Leakage Assay
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL), and
carboxyfluorescein was purchased from Sigma-Aldrich (St. Louis, MO). Lipid vesicles were
created to encapsulate carboxyfluorescein, which upon disruption of the membrane leaks into
the surrounding buffer.
Carboxyfluorescein is a highly fluorescent molecule, which allows its concentration
to be measured by a constant scanning spectrofluorometer. This concentration then gives an
indication as to the degree to which the membrane is permeabilized by the peptide. Baseline
controls were compared to runs with added peptide and added detergent (which acted as a
positive control to give 100% leakage). Percent leakage could then be plotted versus time to
monitor membrane disruption.
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The vesicles were prepared by taking 5 mg of a 7:3 ratio of the lipids 1,2-dioleoyl-snglycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-(phospho-L-serine)
(DOPS), respectively (a zwitterionic and a negatively charged phospholipid mixture that
mimics the -cell membrane), and dissolving in 2 ml of chloroform. The chloroform was
evaporated by a gaseous nitrogen stream to create a thin film of lipid on the side of a test
tube, which was then dried in a vacuum dessicator overnight. 500 l of 30 mM
carboxyfluorescein dye in pH 7.5 sodium phosphate buffer solution was added to the
previously prepared dried lipid to make multilamellar vesicles (MLVs). This solution was
vortexed thoroughly to mix the components and then subsequently frozen using liquid
nitrogen and thawed five times consecutively.

This solution was then extruded 21 times through a polycarbonate filter (pore size100
nm) using a mini-extruder from Avanti Polar Lipids, fitted with two 0.5 ml Hamilton gastight
syringes, producing large unilamellar vesicles (LUVs). To remove nonencapsulated
carboxyfluorescein, the LUV solution was placed on a Sephadex G50 gel exclusion column
and the first colored fragment, the separated dye-containing vesicles, was collected. A vesicle
solution without dye was made the same way except that it lacked carboxyfluorescein and
was not run through the gel exclusion column.

For the assay, a small amount of the dyed vesicle solution was diluted with the vesicle
solution without dye so that the stock vesicle concentration was 15.5 ± 1.5 mM, and the
concentration of lipid in the well was roughly 207 M. In the wells, the ratio of lipid to
peptide therefore ranged from approximately 200:1 to 2:1.
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The isolated LUVs containing the carboxyfluorescein were analyzed using scanning
FT–Vis spectroscopy to determine that the wavelength of maximum absorption was 490 nm.
Using a scanning spectrofluorometer, the wavelength of maximum absorbance was set as the
excitation wavelength and the emission wavelength was determined to be 520 nm.

To make the peptide solution, a weighed sample of the purified peptide was dissolved
in a measured volume of dimethyl sulfoxide (DMSO) and sonicated for 1 minute. Previous
control runs in the absence of peptide confirmed that DMSO itself did not induce dye
leakage. An aliquot of 40.0 l of the vesicle solution was added to sodium phosphate buffer
to a final volume of 3.00 ml in a 5 ml test tube. The peptide solution was added in aliquots, in
increasing amounts per sample; final concentrations varied from 0.5 to 50 M for most
peptides (90 M for the smaller fragments). Upon adding the peptide solution, the test tubes
were mixed by inversion, and 300 l from each tube were transferred to a well in a 96 well
plate, which was inserted into the FLx 800 Fluorescence Microplate Reader (BioTek
Instruments, Winooski, VT) with KC4 software (filter set to 485 nm excitation, 528 nm
emission). A time-course fluorescence spectrum was taken over 180 minutes (3 hours). The
control used to determine 100% leakage was detergent, 40.0 l Triton X (10% v/v in buffer),
which induced the release of any remaining dye from vesicles, resulting in the highest
possible fluorescence. The spectra were saved and numeric values were compiled in
Microsoft Excel. All assays were run three times in triplicate and average values were
reported.
Dye leakage was calculated using the following equation:
Percentage of dye leakage = F - Fbaseline / Fdetergent - Fbaseline , where Fbaseline is the
fluorescence of the LUVs in the absence of peptide (solvent only).
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3.2 Thioflavin T (ThT) Assay

The Thioflavin T assay is similar in procedural detail to the carboxyfluorescein assay
described in earlier sections except that Thioflavin (ThT) is used to identify the degree of
amyloidogenesis following liposome damage. In short, liposomes or lipid vesicles of 7:3
DOPC/DOPS were prepared exactly as described in the carboxyfluorescein assay with the
Thioflavin T dye replacing carboxyfluorescein in the center of each vesicle.

Thioflavin T, a cationic benzothiazole dye was first introduced by Vassar and Culling
in 1959 to demonstrate the presence of amyloid in tissue sections. The enhanced degree of
fluorescence of ThT upon its binding with amyloid was used as a positive indication of the
presence of amyloid. The detection of amyloid by ThT in kidney sections after differentiation
in acidic solutions was also proven to be highly specific by these two scientists. Later, in
1967, two pathologists Saeed and Fine confirmed these findings and established the
superiority of ThT in amyloid detection by careful comparison of Congo red, crystal violet,
van Gieson, and ThT dyes and their binding to several positive and negative control tissues.
ThT was found to have the highest quantitative sensitivity for detection of amyloid in tissue
samples (from clinical cases of amyloidosis) although green birefringence with Congo or
Sirius red was more specific (24).
The potential application of ThT for amyloid identification has been exploited ever
since. It is interesting to note that more recently in 2004, uncharged derivatives of ThT that
readily enter the brain have been used in vivo to establish the presence of Beta amyloid, a
peptide implicated in the causation of Alzheimer’s disease (25).
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The chemical structure of Thioflavin T, (Figure 17) has a centrally located phenyl
group with a hydrophobic dimethylamino group attached on one side while the other end
contains a more polar benzothiazole group (N and S). This combination of polar and
hydrophobic regions supposedly allows Thioflavin T molecules to form micelles in aqueous
solution. These micelles likely contain hydrophobic interiors while the externally oriented
polar N and S groups interact with the solvent. Research groups in this area suggest that the
thiazole nitrogen of the dye and hydroxyl groups of tissue structures most likely form
hydrogen bonds (26,27) during specific binding of the dye molecules to amyloid (Figure18).

Figure 17. Thioflavin molecular structure.

Figure 18. Thioflavin T-Amyloid binding.
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The molecular mechanism of Thioflavin-T binding to amyloid fibrils is still under
current investigation (28). It has been proposed by Khurana et al. (26) that Thioflavin T
molecules were in micelle form at concentrations above 4 M in aqueous solvents as
observed by the increase in the specific conductance. Formation of micelles was also
associated with increased fluorescence excitation and emission of ThT. Additionally, ThT
micelles were observed to bind to the surface of amyloid fibrils confirmed by atomic force
microscopy. Binding of ThT micelles to amyloid fibrils causes changes in the excitation
spectra and enhanced emission fluorescence. Many interactions with ThT are supposedly
mediated predominantly by aromatic side-chains, particularly Tyr and Phe of the amyloid
fibril. The large hydrophobic surfaces provided by these side chains allow ThT binding and
additional fibril π-stacking with the dye may be another key component of these amyloid-dye
binding interactions.

To summarize, the chemical attribute of ThioflavinT causing an enhanced degree of
fluorescence on binding during amyloidogenesis has been exploited in this assay and aids the
evaluation of the amyloidogenic potential of the hIAPP fragments. For over 50 years, the
success of ThT as an amyloid dye has resulted from its broad staining capacity, extraordinary
sensitivity and ease of use. These considerations have made it among the most widely used
dyes for monitoring amyloid formation. ThT's robust staining properties continue to form the
basis of innovative methods for the detection and analysis of fibrils both in vitro and in vivo.
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Further investigations into the molecular mechanism of ThT interactions are needed
to advance our understanding of amyloid formation, kinetics, structure, and pathogenesis.
Insights from such investigations will assist those who design amyloid probes and those who
apply them in research and diagnostic settings.
The recent intense study of the molecular mechanism of ThT binding suggests it may
be possible to apply structure-guided design to modulate the specificity of ThT to particular
amyloid fibrils. Moreover, as a representative amyloid dye, understanding ThT interactions in
atomic detail will ultimately guide therapies to treat amyloid diseases.

Thioflavin T (ThT) was purchased from Sigma-Aldrich (St.Louis, MO). The
conditions for the ThT experiments were the same as for the leakage experiments, with tubes
containing 25 M ThT, in place of carboxyfluorescein; peptide concentration was 25 M and
lipid concentration was 430 M for this assay. The 96-well plate was placed in the FLx 800
Fluorescence Microplate Reader with KC4 software (filter set to 450 nm excitation, 485 nm
emission). A time-course fluorescence spectrum was taken over 300 minutes. Each assay was
run three times in triplicate. A sigmoidal increase in fluorescence intensity over time
indicates amyloid fiber formation by the fragment being tested.
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3.3 Circular Dichroism Spectroscopy and its application for analysis of biologically
useful molecules: brief overview

The phenomenon of circular dichroism was pioneered by three scientists, Jean Bapiste
Biot, Augustin Fresnel and Aime Cotton in 1895 and has been exploited in a wide range of
applications in diverse fields. Circular dichroism spectroscopy (CDS) is the method of
chemical analysis of molecules by making use of the differential absorption of left and right
circularly polarized light by different portions of optically active chemical molecules (29,30).
The phenomenon of circular dichroism is exhibited in the absorption band of many optically
active molecules and ultraviolet CD spectroscopy is most commonly used to investigate
secondary structures of proteins (31). Another variety, vibrational CDS uses infrared light for
structural examination of small organic molecules and, most recently, proteins and DNA.

While the dextrorotary and levorotary components of molecules provide important
information, the secondary structure of a protein imparts a distinct CD spectrum that is
unique to the particular molecule. Hence, the alpha helix and beta sheet of proteins and
double helix of DNA have CD spectral signatures that represent or provide clues to their real
structures. The ability of CDS in providing a representative structural signature makes it a
powerful tool in modern biochemistry with wide ranging applications.
The far-ultraviolet (UV) spectrum (200 – 122 nm) of proteins usually reveals
important characteristics of their secondary structure while the near-UV CD spectrum (400300 nm) provides information on the tertiary structure of the protein. A high pressure, shortarc xenon lamp is the usual light source in these instruments.
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The CD spectra can be readily used to estimate the fraction of a molecule that is in the
alpha helix, beta sheet, beta turn or random coil conformations. These fractional assessments
limit the possible number of secondary conformations that the protein can assume and act as
a rough guide in predicting their structure. CDS, however, cannot precisely estimate the
location and number of alpha helices within a given molecule. Inspite of this, CD remains a
valuable tool especially for showing changes in conformation with corresponding changes in
temperature or concentration of denaturing agents interacting with molecule being examined.
CDS is also a valuable tool for verifying that a protein is in its native conformation before
undertaking extensive and/or expensive experiments.

Since CDS is usually used to study proteins in solution, it complements methods that
study the solid state. Also, while techniques such as X Ray Crystallography and Protein NMR
Spectroscopy provide specific structural detail of proteins with atomic resolution data, CD
spectroscopy is a quick method that does not require large amounts of proteins or extensive
data processing. Thus, CDS can be used to survey a large number of proteins with differing
conditions related to temperature, pH and salinity in a relatively short time, thus increasing
thoroughput.

Methodology of Circular Dichroism Spectroscopic Analysis
The lyophilized peptide samples were dissolved at a concentration of 25 M in 10
mM sodium phosphate buffer at pH 7.5, vortexed and sonicated for 15 s and transferred to a
0.1 cm quartz cuvette. After the initial baseline spectrum of the peptide alone in solution was
taken, liposome vesicles of 7:3 DOPC/DOPS (prepared as described in earlier sections) were
added to the cuvette from a 40 mg/ml stock solution to achieve a final concentration of 400
M, and another spectrum was taken after 1 hour.
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Spectra were measured at room temperature (23C) on an AVIV circular dichroism
spectrometer (Lakewood, NJ) at 1 nm intervals from 190 to 260 nm at a scanning speed of 50
nm/min and a bandwidth of 5 nm. Each spectrum reported is the average of four scans
(peptides alone) or eight scans (peptides plus vesicles) after subtraction of the baseline
spectrum (without peptide). The results obtained from CD Spectroscopy are considered
qualitative as the use of optical methods like CD are parameterized for large proteins and thus
involve some uncertainty in its application to secondary structure determination of short
peptides such as the peptides in our experiment (21).

3.4 Molecular Modeling Experiments:

Molecular modeling techniques encompass all the theoretical and computational
methods that are used to model or mimic the behaviour of molecules. The techniques are used
in diverse fields including computational chemistry, biology and material science for
studying molecular systems ranging from small chemical systems to large biological
molecules and material assemblies. While manual calculations can be made for the smaller
and often simple systems, computer programs and methods must be utilized to achieve
molecular modeling of larger systems (32,33).

The molecular modeling techniques describe molecular systems at the atomistic level
where the lowest level of information is related to individual atoms or a small group of
atoms. A more explicit evaluation of a system or molecule is made in quantum chemistry
which makes use of electronic structure calculations and the functional influence of electron
distribution within a system.
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While the benefit of molecular modeling allows many more particles or atoms to be
considered during simulations and reduces the complexity of a given system; quantum
analysis facilitates detailed evaluation of the subatomic components by analysing the
electronic distribution within a system. Molecular modeling simulations can be achieved
either in vacuum, known as gas phase simulations, or in the presence of a solvent such as
water, referred to as explicit solvent simulations. Simulations that do not make direct use of a
solvent but theoretically estimate the effect of solvent by using empiric mathematical
expression are known as implicit solvation simulations.

Molecular modeling methods are currently utilized on a routine basis for investigating
the structure, dynamics, surface properties and thermodynamics of inorganic, biological and
polymeric systems. Several types of biological activity have been investigated using
molecular modeling including protein folding and stability, catalytic activity of enzymes,
conformational changes leading to differences in biomolecular function and molecular
recognition of proteins and DNA.

Density functional theory (DFT) is a quantum mechanical modeling method used in
physics and chemistry to investigate the electronic structure of systems such as atoms,
molecules and the condensed phases. Using this method, the properties of a multi-electron
system can be determined by using functionals, i.e., functions of another function, which in
this case is the spatially dependent electron density. Hence, the name density functional
theory comes from the use of functionals of the electron density. DFT is among the most
popular and versatile methods available in condensed-matter physics, computational physics
and chemistry.
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Modeling Calculations

All modeling calculations on our peptide fragments and the full length hIAPP were
carried out using the GaussianTM suite of programs (Gaussian 03, 2004) on EMU’s Dell
PWS quad-core processor, MacPro eight-core processor, or on the National Center for
Supercomputing Applications’ SGI Altix cluster (34). An independent research group led by
Dr. Maria Milletti and working on computational chemistry applications was involved in all
the modeling calculation work related to these peptide fragments. Molecular structures of the
monomers in the gas phase were constructed using the GaussView (GaussView4, 2004)
visualization program and then optimized employing Density Functional methods (33,35,36).
Specifically, the hybrid method B3LYP was used, which includes Becke’s three-parameter
exchange-correlation hybrid functional (37) and the correlation functional of Lee, Yang, and
Parr (38). The 3-21G* basis set was used for all calculations (39,40, 41,42,43,44). The Berny
algorithm was employed to optimize all structures to a minimum energy (45, 46, 47, 48).
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4. Results and Discussion
4.1 Liposome dye leakage assays: Carboxyfluorescein and Thioflavin T Experiments
The sequences of the synthesized fragments and purchased full length hIAPP, as well
as rat IAPP (rIAPP), are shown in Figure 19.
20-29 SNNFGAILSS
10-19 QRLANFLVHS
10-29 QRLANFLVHSSNNFGAILSS
1-19

KCNTATCATQRLANFLVHS

1-37

KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY

rIAPP KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY
Figure 19. Sequences of hIAPP fragments and rIAPP (human and rat).

In these two dye assays, membrane vesicles either filled with carboxyfluorescein or
treated with Thioflavin T were allowed to react with varying concentrations of the
synthesized peptide fragments. The data shown in Figures 20 and 21 were gathered from the
carboxyfluorescein dye leakage assay showing the interaction between the pancreatic beta
cell analogs (liposome vesicles comprised of a 7:3 ratio of the lipids DOPC and DOPS) and
varying concentrations of the hIAPP fragments ranging from 0.5 to 50 M (or higher in the
cases of the shorter, lower molecular weight analogs). The fluorescence measurements
indicative of dye leakage from the vesicles or dye reacting with hIAPP fibrils were recorded
every minute for 3 hours, and average percent dye leakage values relative to test controls
were obtained. In case of ThT assay the time of the characteristic increase of fluorescence,
indicating fibril formation (if any) was noted.
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Two specific time points were chosen for studying the temporal effects of the
interactions between the peptide fragments and the liposomes in the carboxyfluorescein
assay, the initial time point at the beginning of the experiment revealing the peptide
fragments with the highest and most rapid destructive potential and the final end point 3
hours later showing the increasing destructive potential of peptide fragments with longer
periods of interaction with the liposomes. Figure 20 represents the initial percent leakages,
and Figure 21 shows the effect of the peptides on the integrity of the vesicles after 3 hours.
Disruption of the vesicles by the peptide allows dye leakage from the vesicles into solution,
leading to elimination of the self-quenching effect and increasing carboxyfluorescein
fluorescence.
In our experiment we used both positive and negative controls for validating our
results. The positive controls with 100% dye leakage due to total liposome disruption were
set up by adding chemical detergent to solutions containing the dye encapsulated liposomes,
without any peptide fragments. In contrast, the negative controls, with no expected dye
leakage, were made up of liposomes alone in solution without addition of peptide fragments
or detergent that would otherwise cause membrane disruption. The results obtained provide
an assessment of the degree of vesicle disruption caused by each of the synthesized peptides
at varying concentration levels. Baseline controls were compared to runs with added peptide
(causing less than 100% leakage) and added detergent (which acted as a positive control to
give 100% leakage). Percent dye leakage was then plotted against time to identify the
temporal changes in peptide liposome interactions leading to worsening membrane disruption
with almost all peptides and corresponding increase in fluorescence.
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Results of the Carboxyfluorescein assay
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Figure 20. Initial dye leakage from DOPC/DOPS (7:3) vesicles (0.21 mM) caused by varied
concentrations of hIAPP peptide fragments; values represent the average of three trials.
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Average Membrane Disruption at 3 hours
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Figure 21. Final (3 hour) dye leakage from DOPC/DOPS (7:3) vesicles (0.21 mM) caused by
varied concentrations of hIAPP peptide fragments; values represent the average of three
trials.

4.2 Thioflavin T assay
As discussed in the methodology section, the chemical Thioflavin T (ThT), is a dye
that is commonly used for the detection and quantification of amyloid fibrils. The
amyloidogenic potential or the ability of individual peptide fragments to form amyloid fibrils
after liposome disruption was measured by an increase in ThT fluorescence intensity caused
by Thioflavin T binding or specific chemical interaction with beta sheet rich structures found
in amyloid aggregates.
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The enhanced fluorescence of ThT is revealed by a characteristic red shift of the ThT
emission spectrum detected by the spectrofluorometer. The time duration of this assay was
also scaled to a period of 5 hours so as to measure the amount of time required for the peptide
to fibrillize. It is also worthwhile to note that amyloid fibril formation for the full-length
peptide showed a sharp increase at 2.5 hours and reached a maximum intensity. A relatively
constant fluorescence intensity over the time period examined reflects the absence of fiber
formation for the fragment peptides. Results of this assay are presented in Figure. 22.
Thioflavin T Assay
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Figure. 22. Thioflavin T Fluorescence Intensity in the Presence of 25 M hIAPP or Peptide
Fragments Over Time.
The most obvious observation was the concentration dependence of peptide fragments
on liposome vesicle damage. As anticipated, the full length hIAPP peptide was the most
destructive and caused greater than 60% initial and 100% final (total vesicle destruction) dye
leakage at 50 M which is the highest concentration that was tested. A logarithmic regression
for peptide concentration versus liposome damage with correlation coefficients of 0.81 and
0.87 is shown respectively, for initial (Figure. 20) and final (Figure.21) fluorescence
readings.
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It was also observed that membrane leakage increased significantly over the three
hour time period and possibly may be attributed to amyloid aggregate formation, which
worsens liposome destruction and related dye leakage. The concentration of peptide and
presence of lipids influence the half life of amyloid fiber formation which has been reported
as 60 minutes by earlier studies (20,49). In the ThT assay (Figure 22) a sharp spike in
fluorescence was noted at 2.5 hours for the full length peptide only, suggesting amyloid fiber
formation, that was maximized at three hours. In addition, Figures 20 and 21 reveal an
obvious difference in the liposome leakage data between the lower peptide concentrations
and 10 M, indicating a 10 M threshold required for inducing significant membrane damage
in this assay.
As expected, the second most destructive fragment in this assay was the 1–19
segment. This fragment contains the N-terminal region, which is believed to induce transient
membrane disruption by directing the binding or insertion of the peptide into the liposome
membrane, inducing a first phase of damage. In the case of the full length hIAPP, this step is
then followed by amyloid aggregate formation (50,51). This initial peptide-membrane
interaction may be attributable to the positive charges in this region at amino acid positions 1,
11, and 18 (K, R, H) that attract it to the negatively charged phospholipid groups. However,
this 1–19 segment alone does not have the capacity to cause amyloid aggregation (21), as it
lacks the amyloidogenic 20–29 region. Consequently, the ThT assay (Figure 22) confirmed
the absence of fiber formation for this fragment. This fragment is increasingly destructive in
this assay over time and causes up to 60% dye leakage after 3 hours (only 17% initially) at 50
M.
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However, it should be noted that a clear minimal concentration is required, as
effectively no dye leakage was incurred by concentrations tested that were lower than 10 M.
This pattern is similar to that observed for full length hIAPP except that the extent of damage
is lower.
A logarithmic regression of the relationship between peptide concentration and
percent dye leakage is shown in Figures 20 and 21 with correlation coefficients of 0.85 and
0.86, respectively. In general, the final dye leakage caused by this peptide was approximately
30% less than that caused by hIAPP itself at analogous concentrations (Figure 21), and initial
dye leakage was considerably lower (Figure 20). Our results are roughly comparable to those
of Brender et al. (21), who reported that the hIAPP 1–19 peptide is approximately as active as
the full length peptide in POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol)
liposome disruption at low concentration; however the study found that at higher
concentrations, hIAPP 1–19 actually was more active than the full length peptide. The
variability between results from our study and this previously published data may be
attributed to the different lipid composition of the vesicles; POPG is more negatively charged
than the 7:3 DOPC/DOPS mixture which is generally considered a good mimic of the islet
cell. The 1–19 fragment is capable of both inducing negative curvature in lipid bilayers (52)
and causing intracellular calcium release (53). Overall, it is clear that amyloid fiber formation
is not a requirement for membrane damage.
The 20–29 region of hIAPP has long been speculated to mediate the aggregation of
the amyloid fibrils (19, 20). This amyloidogenic region however has limited cytotoxicity on
its own relative to the full length peptide, despite its ability to form fibrils (20, 54).
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Data from this study support that finding, as this fragment was observed to be the
least destructive of the fragments tested (Figures 20 and 21). While lower concentrations of
the 20-29 peptide (below 20 M) failed to cause any dye leakage from the vesicles, higher
concentrations (up to 90 M) induced weak dye leakage, at the maximum, up to 10%.
Additionally, there was no significant increase in liposome damage over the extended 3 hour
time period of the carboxyfluorescein assay and no fiber formation was observed on the ThT
assay (Figure 22). This lack of activity by the 20-29 peptide fragment is in stark contrast to
the extensive magnitude of liposome damage by the full length hIAPP. Our data support the
theory that the 20–29 fragment may require the presence of some other region of hIAPP
peptide in order to cause liposome damage. Most likely, this is the more positively charged
N-terminal region of the native peptide, which is believed to direct insert into the membrane
(50,51). Since this fragment lacks the positive charges that are present in the N-terminus, it
does not experience a large degree of electrostatic attraction to the membrane by itself.
The 10–19 fragment contains a weakly amyloidogenic region (56); however, whether
it could induce membrane disruption by itself was unknown. This fragment binds to a region
of insulin, possibly via pi-stacking interactions between aromatic residues, in a process that
has been reported to inhibit fiber formation and limit cell membrane damage (11). Similar to
the results of the 20–29 fragment from the dye leakage assay, data for this fragment
demonstrate its inability to induce a great extent of dye leakage from the vesicles (Figs. 20
and 21) or to form amyloid fibers within the examined time period (Fig. 22). In fact, while
the vesicle damage was slightly higher than that incurred by the 20–29 fragment (10–20%
leakage), there was neither any observable concentration dependence nor significant increase
of activity with time.
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Despite the presence of two of the three positively charged amino acid side chains
(positions 11 and 18) in the 10-19 fragment, which would theoretically allow higher
electrostatic attraction to the liposomes relative to the 20–29 fragment, this fragment also
fails to cause significant membrane damage. Although there is no direct evidence from this
study that greater positive charge influences membrane damage, there is undoubtedly a
correlation within this group of peptide fragments, where fragments with greater number of
positively charged amino acids have shown higher levels of membrane destructive potential.
This relationship and the theory that electrostatic interactions with membrane phospholipids
accelerate hIAPP misfolding and subsequent activity have been supported by earlier studies
(56). Additional support to these views is provided by results showing higher activity for all
fragments with negatively charged POPG vesicles and lesser degree of activity in zwitterionic
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) vesicles compared to our vesicles
composed of 7:3 DOPC/DOPS (from unpublished data obtained by our group).
Interestingly, the 10–29 fragment which is a combination of two relatively inactive
and shorter fragments (the 10–19 and 20–29 peptides), showed perceptible activity in the dye
leakage assay, which was noticeably higher than that seen with either of the two shorter
fragments. The concentration dependence fit a logarithmic regression, with a correlation
coefficient of 0.86 for the initial reading (Fig. 20) and 0.88 for the 3 hour reading (Fig. 21).
The possible explanation for these findings perhaps relates to a membrane disturbing
conformation adopted by the longer sequence that understandably cannot be achieved by
either of the two shorter fragments. This idea was also proposed by Kajava et al. (57) who
hypothesized a planar S-shaped folded structure for the 9th through the 37th amino acid
residues of hIAPP, with three beta strands comprised of the segments 9–19, 20–29, and 30–
37, respectively.
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These strands are proposed to stack together to generate three parallel beta sheets in a
cross-beta conformation. The 10–29 fragment, which contains the two smaller fragments that
are required to form beta sheets according to this theory, may possibly assume a turn
structure that can form similar stacked beta sheets. However, the ThT assay results for the 1029 fragment failed to demonstrate perceptible amyloid fiber formation despite a moderate
degree of liposome damage (Figs. 20, 21, 22), implying that its ability to disrupt liposomes is
independent of amyloidogenesis. Alternatively, the 10–29 fragment may be long enough to
insert into the membrane and still allow self-interaction at its C-terminus (the 20–29 region).
At similar concentrations, this peptide was about half as active as the N-terminal 1–19
fragment and approximately one-fourth as active compared to the full length hIAPP. At the
highest concentrations tested for this fragment (70 and 90 M), which were higher than the
concentrations tested for the full length peptide and the 1-19 sequence, dye leakage
approached 50% after 3 hours (Fig. 21). Additionally, at all concentrations tested, there was a
clear demonstration of increasing liposome damage with time. The worst degree of damage
by this fragment, however, does not match up to the maximum damage impacted by the full
length hIAPP. An important point to note with this 20 amino acid peptide is the presence of
the His residue at the 18th position, which has been implicated in modulating the peptideliposome membrane interaction in the human versus rat form of IAPP 1–19, thereby likely
playing a key role in the cytotoxicity of non-fiber forming forms of the peptide (53). The rat
form of the 1-19 peptide has the R instead of H at 18th position and renders the fragment
inactive with little or no liposome destructive potential. Though we did not utilize the rat
form of IAPP in our dye leakage assays, we compared results related to this peptide from
earlier studies using CD spectroscopy and molecular modeling to extrapolate some of our
results, in order to achieve some of our final conclusions.
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In summary, our data support the two-step model where hIAPP first induces transient
permeabilization and possible pore formation resulting in eventual liposome destruction.
Smaller peptide fragments may not be able to adopt the same conformation as the full length
analog during this process. The initial effect of peptides on the liposome membrane is
observed to be destructive by itself (the first step), and is independent of amyloid fibril
growth. In fact, this process may be a prerequisite to amyloid fibrillogenesis and growth, the
second step of our proposed two step model. The initial step appears to be most likely
mediated by the overall positively charged N-terminal 1–19 region of the peptide, as
according to our data, this peptide fragment induced considerable membrane damage despite
its inability to form amyloid fibers. Indeed, each short amyloidogenic region by itself did not
induce extensive damage in this membrane model assay within the 3 hour time frame
observed. We speculate that this may be due to a relative lack of overall positive charge
required for electrostatic attraction to the membrane surface (20–29), or could be due to
relatively shorter length or inability to insert into the membrane (both 10–19 and 20–29). The
longer 10–29 fragment, which carries two of the three side chain positive charges of the 1–19
region, may be able to insert its N-terminus into the membrane with subsequent selfinteraction of the amyloidogenic region on the membrane surface, giving it overall
intermediate level activity. The other feature of this fragment could possibly relate to its
ability to form a turn structure, similar to part of the proposed S-shaped fold, which can stack
and generate the beta sheet structures found in amyloid fibers (57). Future experiments to
determine whether surface binding is occurring will shed more light on the stepwise process
of membrane interaction for these fragments.
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While the positively charged N-terminal part of hIAPP appears to be necessary for the
initial membrane interaction, it is the C-terminal region that most likely drives the
oligomerization and subsequent amyloid fiber formation required to complete both the
proposed steps in this molecular process. In the beta-structure model described above, the Nterminal 1–8 region is excluded from the serpentine turn and is free to interact with the
membrane (57). It has been reported that hIAPP molecules tend to cluster in a trans-bilayer
fashion in the membrane before fibrillization, with their N-termini directed toward the bilayer
(56). Indeed, the reason that pre-formed fibers are not cytotoxic is likely due to their inability
to insert into the membrane (51). Thus, we can conclude from the results of the dye leakage
assays that a two step mechanism requires the entire hIAPP sequence. This can reasonably
justify the extensive membrane damage occurring in the presence of the entire hIAPP
molecule.
The association of peptide monomers into oligomers may eventually form channels
through the cell membranes, leading to the leakage of cell contents and subsequent cell
destruction (58). Other similar studies support a mechanism where hIAPP induces formation
of small surface defects (59) or causes negative membrane curvature (52) which progresses to
more extensive membrane damage. Any of these mechanisms is possible for the damage
induced by the N-terminal region. It is also possible that, after hIAPP inserts into the
membrane, there is a nucleation step leading to membrane fragmentation by the incorporation
of lipid molecules into the amyloid fiber as it grows, and that fiber-making process
accentuates the cytotoxicity (60).
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4.3 Molecular Modeling and Circular Dichroism Experiments

The full length human IAPP, rat IAPP and all the previously examined fragments of
the hIAPP molecule (Fig. 16) were analyzed and compared using molecular modeling. In
addition, hIAPP fragments 10–19, 10–29 and 20-29 were analyzed by circular dichroism,
followed by comparison to published CD data for the full length hIAPP and 1–19 analogs, to
examine possible secondary structure.

The modeling calculations were mainly used to investigate two functionally relevant
aspects of the fragments: charge distribution, as shown by the electrostatic potential mapped
onto the total density surface, and propensity for aggregation dependent upon the overall
shape/conformation attained by the fragment. Although the calculations were carried out in
the gas phase, in the absence of phospholipids, the high level of theory employed here
provides a very accurate depiction of the structural and electronic characteristics that
ultimately influence the behavior and activity of the peptides.
In addition, the observed differences between the human and rat forms are very
unambiguous, given their obvious differences and thus providing added confidence to our
conclusions. According to modeling calculations the presence of predominantly positive
charges at either end of the 1-19 fragment (1, 11, 18th amino acid positions) must allow this
fragment greater ability to interact with the negatively charged membrane phospholipids. The
dye leakage assay results reveal a high degree of liposome membrane destruction by this
fragment, thus providing positive correlation with the conclusions derived from the molecular
modeling calculations. The lack of the suspected amyloidogenic region, 20-29 within this
fragment, correlates well with the absence of significant fibril formation in the ThT assay.
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Another assumption that we can derive is that monomers exhibiting an open, mostly
linear structure are able to form several intermolecular bonds (such as hydrogen bonds and
electrostatic interactions), thus leading to dimer formation and eventually aggregation. This
hypothesis is confirmed by comparison of the information obtained by computational
analysis of the human and rat forms of IAPP, and both their respective amyloidogenic 20–29
fragments.

It is well known that rIAPP and the 20–29 fragment of rIAPP do not form amyloid
deposits, unlike their human counterparts (19). In accordance with this hypothesis, we find
that the optimized structure of hIAPP is linear and quite open, showing a 130 angle at
residue Leu (27th position); in contrast, the structure of rIAPP is folded onto itself, with a
loop comprising residues 20–37 (Fig. 23). The same is true of the 20–29 fragments: the
human peptide optimizes to a mostly linear shape, while the rat peptide folds onto itself, the
folding likely contributing to its inability for dimerization/oligomerization. The slightly bent
but relatively linear shape obtained for the 20-29 fragment of the hIAPP molecule agrees with
several published studies. Additionally, results from our dye leakage assays also ascertain this
fragment’s higher amyloidogenic potential, likely related to higher probability towards
oligomerization.
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(a)

(b)
Figure 23. Optimized structures of (a) hIAPP and (b) rIAPP. Hydrogen atoms are omitted
for clarity.
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Atomic structure data from modeling studies have revealed that residues 21–27 of
hIAPP contain a small bend at the central Gly residue, facilitating the alignment of the
segment in beta sheet layers upon aggregation (61). NMR and diffraction data confirm that
the 20–29 segment has a mostly linear structure with a bend at Gly24 (62). In addition, when
hIAPP interacts with negatively charged micelles, three amino acid residues, Phe, Ala, and
Ile (23, 25, 26) form a small hydrophobic cluster that faces the hydrocarbon region of the
liposomes/micelles, due to a distorted beta turn at residues Phe (F) and Gly (G) at the 23 and
24 positions of hIAPP, detected by NMR (61). This is in line with our optimized structure,
where the ordered side chains of these residues are on the same side of the peptide backbone.
It has also been proposed that charge–charge interactions and hydrophobic cluster formation
drive the aggregation process (63). Accordingly, our optimized structure shows both charged
and neutral side chain moieties that are easily accessible and prone to aggregation.

In terms of charge distribution, we observe that the 1–19 fragment monomer
containing all the 3 positively charged amino acids has by far the most positive charge
distribution at its N-terminus compared to all the fragments studied. However, the 1–19
fragment has a 110 bend at the Tyr9 residue while the 10–29 monomer fragment adopts an
almost circular configuration likely due to different conformational influences. Optimized
fragment structures are shown in Figure 24 on the next page. Electron density maps of the
fragments and hIAPP are shown in Figure 25. In addition, we found that the shorter 10–19
and 20–29 fragments have mostly linear structures, which may be compatible with possible
clustering and amyloid formation, although the ThT assay did not support fibrillization of
these analogs.
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(a)

(b)

(c)

(d)
Figure 24. Optimized structures of hIAPP fragments (a) 1-19, (b) 10-19, (c) 20-29 (d) 10-29.
Hydrogen atoms are omitted for clarity.
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(a)

(b)

(c)
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(d)

(e)
Figure 25. Electron Density Maps of (a) 1-19, (b) 10-19, (c) 20-29 and (d) 10-29 Fragments
and (e) hIAPP. Surfaces are constructed by mapping electrostatic potential onto the total
electron density. Blue shaded regions indicate localized positive charge.
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These computational results are in agreement with the experimental data which
indicate that the 1–19 fragment causes the greatest liposome damage, supposedly by inserting
into the membrane with its positively charged N-terminus, but does not form fibers, given its
L-shaped structure. In fact, circular dichroism (CD) spectra have indicated that this fragment,
similar to hIAPP 1–37, initially adopts a random coil conformation in buffer, and
immediately converts to an alpha helix in the presence of negatively charged lipids. However,
unlike full length hIAPP, there is no subsequent conversion to the beta sheet structure that is
usually associated with amyloid fiber formation (21).
The computational data for fragment 20–29 is also in line with the accepted view, that
despite low levels of liposome membrane damage due to lack of concentration of positive
charge at its N-terminus (confirmed by the electron density distribution map) this fragment
has better ability to form amyloid fibrils, given its mostly linear shape. Based upon CD
studies, an extended beta sheet structure has been reported for this segment following four
days of peptide aging in solution (64), which agrees with our linear model. While CD spectra
that show a pronounced double minimum at 210 and 225 nm usually indicate an  helical
configuration of the peptide fragment being tested, a single minimum at 220 and 195 nm
reflect a  sheet and random coil secondary structure, respectively.
Our CD analysis of the 20–29 segment, on the same 3 hour time scale as published
CD studies of hIAPP 1–19 and 1–37 (21) and that of the dye leakage assay, indicates that it
initially adopts a random coil structure in buffer like the other fragments (Figure 26).
However, its persistent unstructured conformation an hour after the addition of lipid vesicles
(Figure 27) suggests that the lipids do not influence its conformation as they do for the Nterminus containing peptides. This feature also reiterates the finding from the ThT assay that
fragment 20–29 is not aggregating within this time frame.
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Figure 26. CD Spectra of fragments 10-19 (green dotted line), 20-29 (blue dashed line) and
10-29 (red solid line) in pH 7.5 sodium phosphate buffer at 25 M.
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Figure 27. CD Spectra of fragments 10-19 (green dotted line), 20-29 (blue dashed line) and
10-29 (red solid line) in pH 7.5 sodium phosphate buffer at 25 M one hour after addition of
400 M 7:3 DOPC: DOPS vesicles.
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Segment 10–19 also has a linear optimized structure and, although its charge
distribution is fairly neutral and we would not expect it to be extensively attracted to the
membrane, we would expect it to dimerize quite readily, as it reportedly does within the full
length peptide (51). Our CD analysis indicates a random coil structure for this peptide, both
in buffer alone and after the addition of liposomes (Figures 26 and 27). This is in agreement
with published CD spectra for the similar analog hIAPP 8–20, which show this fragment
adopting a random coil conformation in solution, with conversion to the beta sheet
configuration after a four week incubation (51). The electron density map of hIAPP 10–19
shows slightly more localized positive charge near its N-terminus than the 20–29 fragment,
but not as much as the 1–19 and full length peptides, which compares well with their relative
activities.

The most interesting results were obtained for the 10–29 segment: this peptide had
noteworthy membrane destructive activity but there was no evidence of fibril formation. The
optimized conformation of this fragment in the form of an oval loop likely explains the lack
of amyloid fibril formation. This conformation maximizes intramolecular interactions
(between the two ends of the peptide fragment) at the expense of intermolecular interactions
that are required to form dimers and eventually fibrils. However, the loop conformation of
this fragment compares well with the turn of a truncated serpentine “S” shape proposed by
Kajava et al. (57), so stacking of these structures is not precluded. The CD spectra of this
fragment show a negative minimum intensity between 195 and 200 nm, which is indicative of
a random coil arrangement in both the absence (Figure 26) and presence (Figure 27) of
negatively charged lipids.
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There was no evidence of conversion to either alpha helical or beta sheet structures
within the 3 hour time frame monitored, which is in accordance with results from the ThT
assay where there was little amyloid fibril formation even at the end of 3 hours. Though
identical in length and 50% identical in sequence to the 1–19 fragment, hIAPP 10–29 does
not appear to undergo the same degree of conformational change in the presence of
negatively charged phospholipids, which may contribute to its relatively lower fibril forming
activity. The electron density map of this fragment shows some positive charge distribution
near its N-terminus, which may help attract it to the membrane and cause a moderate degree
of liposome membrane damage.

In summary, when compared with previously published data in this area, our results
support a two step model of pancreatic beta cell damage. The hIAPP molecule most likely
exerts its damaging effects by first binding at the surface of the membrane via its positively
charged N-terminal region, transiently disturbing the lipid bilayer core of the cell membranes,
followed by formation of cytotoxic oligomers and eventual amyloid fibers. The first binding
step induces some initial membrane damage which is later followed by the fibrillization
process, gradually increasing the extent of membrane destruction. In fact, the initial
membrane damage may help promote aggregation by increasing the local concentration of
membrane bound hIAPP, or by influencing a conformational change in the membrane.

To further explore the correlation between positive charge distribution and liposome
damage, impending studies will/can be aimed at assessing the activity of analogs where the
positive charge has been masked or replaced. These studies would successfully help confirm
the role of these culprit amino acid residues.
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Concluding Remarks

In our study, peptide fragments of hIAPP were tested for their ability to disrupt
liposomes (used as model pancreatic cell membranes) and cause amyloid fibrillization. These
findings were compared to the activity of the full-length native peptide. While a maximal
effect was seen for full-length hIAPP (the only peptide that formed fibers in our assay),
hIAPP 1–19 was also very damaging to the liposomes. Both of these peptides showed
concentration dependent damage that approached a maximum of 100% and 63% dye leakage,
respectively, after 3 hours at 50 M. The smaller, more amyloidogenic fragments (10–19 and
20–29) were much less damaging to the vesicles by themselves and displayed little
concentration dependence (20% and 10% leakage maximum, respectively, after 3 hours at
50–60 M). However, a combination of the two smaller fragments, the 10–29 sequence
showed moderate liposome destruction with concentration dependent activity (30% leakage
after 3 hours at 50 M). The results of molecular modeling calculations suggest that peptides
with a significant amount of positive charge at the N-terminus (containing amino acid
residues 1,11,18) are more likely to cause membrane damage via increased electrostatic
affinity for the negatively charged liposomes. Conversely, the overall shape of the peptide
fragment influences its ability to form amyloid fibrils: while the linear segments may be more
likely to aggregate, peptides that have sharp bends in their structure may have fewer sites
available for binding to other peptides and thus limited amyloidogenic potential.
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Future work

Translation of our research project to in vivo animal studies would help confirm our
experimental results and be used in preclinical research development. It would lead to highly
regulated temperature, pH, osmotic and chemical environment that is currently not feasible
within our experimental set up.
Increasing health care costs coupled to the World Health Organization’s prediction of
a worldwide Diabetic epidemic by the year 2030, make experimental diabetes research a
crucial prologue to future clinical trials in prevention, diagnosis and treatment of Diabetes
mellitus type II. Identifying causative factors for Diabetes mellitus Type II and extrapolation
of the inferences obtained, to other amyloid associated diseases will lead to substantial
reduction in morbidity and mortality and to the improvement of quality of life for people
suffering from these diseases.
Research in peptide science and technology has the potential to create hitherto
unknown inroads in the emerging fields of molecular imaging and molecular medicine, which
will revolutionize the bench to bedside concept of translational research and clinical practice
in the years to come.
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